Mistel-Therapie bei Krebs

Aussagen in der wissenschaftlichen Literatur:

Heterogeneity of study results was moderate (I2 = 38.3%, p < 0.0001). The funnel plots were considerably skewed, indicating a publication bias, a notion which is corroborated by statistical means (AC = -1.3, CI: -1.9 to -0.6, p <= 0.0001). A random effect meta-analysis estimated the overall hazard ratio at HR = 0.59 (CI: 0.53 to 0.66, p < 0.0001). Randomized studies showed less effects than non-randomized studies (ratio of HRs: 1.24, CI: 0.79 to 1.92, p = 0.35), …
Pooled analysis of clinical studies suggests that adjuvant treatment of cancer patients with the mistletoe extract Iscador is associated with a better survival. Despite obvious limitations, and strong hints for a publication bias which limits the evidence found in this meta-analysis, one can not ignore the fact that studies with positive effects of VA-E on survival of cancer patients are accumulating. Future studies evaluating the effects of Iscador should focus on a transparent design and description of endpoints in order to provide greater insight into a treatment often being depreciated as ineffective, but highly valued by cancer patients.

In dieser Studie ergaben sich für Viscum Album (Iscador®) Hinweise auf beschleunigtes Tumorwachstum. Aufgrund dieses Ergebnisses wird in aktuellen Leitlinien (auch noch im Jahr 2018) von einer adjuvanten Mistelbehandlung bei Melanom-Patienten abgeraten.

Kommentar verfassen

This site uses Akismet to reduce spam. Learn how your comment data is processed.